Saturday 17 October 2026
Export SNWV’s income statement to Excel — free account
Sanuwave Health Inc.
SNWV Healthcare Medical Devices
Sanuwave Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.1 million, up 35.0% from fiscal 2024. In the quarter to June 2026, revenue fell 3.13%, EPS fell 224.2%, free cash flow grew 86.8% and total debt fell 28.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
4.96
0.21
−4.06%
Follow SNWV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 22.70 | 9.58 | 6.02 |
P/S ratio |
7.80 | 5.80 | 3.35 | 1.95 | |
P/FCF ratio |
76.20 | 34.96 | 16.10 | 9.18 | |
P/Operating CF |
297.17 | 76.99 | 374.16 | 202.38 | |
P/B ratio |
0.00 | 157.84 | 80.82 | 30.86 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.14 | 6.03 | 3.57 | 2.18 | |
EV/EBITDA |
42.88 | 34.53 | 28.64 | 28.30 | |
EV/Operating CF |
258.09 | 68.51 | 27.35 | 18.35 | |
EV/FCF |
79.46 | 36.33 | 17.16 | 10.22 | |
Quick Ratio |
0.73 | 0.97 | 0.92 | 0.84 | |
Current Ratio |
1.16 | 1.38 | 1.31 | 1.28 | |
Net Debt/EBITDA |
6.40 | 5.36 | (12.97) | 78.40 | |
Debt/Assets |
65.63% | 58.81% | 55.45% | 52.39% | |
Debt/Equity |
(7.97) | 13.56 | 11.19 | 6.88 | |
Asset Turnover |
1.43 | 1.31 | 1.31 | 1.26 | |
Operating CF/Net income |
0.10 | 0.47 | (0.28) | (0.62) | |
Capex/Depreciation |
6.55 | 0.65 | (0.43) | (1.10) | |
Interest Coverage |
0.85 | 2.13 | (2.06) | (0.54) | |
Research and Development Expense of Revenue |
3.01% | 4.59% | 6.86% | 6.45% | |
Selling, General and Administrative Expense of Revenue |
60.18% | 56.64% | 79.52% | 70.08% | |
Intangible Assets out of Total Assets |
0.29 | 0.28 | 0.27 | 0.28 | |
Share Based Compensation of Revenue |
12.29% | 10.12% | 17.76% | 14.73% | |
Graham Net Nets |
(0.05) | (0.04) | (0.08) | (0.12) | |
Graham Number |
1.97 | 2.36 | 2.95 | 3.48 | |
Earnings Yield |
(1.35%) | 4.40% | 10.44% | 16.60% | |
Free Cash Flow Yield |
1.31% | 2.86% | 6.21% | 10.89% | |
Revenue per Share |
1.34 | 1.54 | 1.12 | 1.13 | |
Operating CF per Share |
0.13 | 0.39 | 0.05 | 0.05 | |
Capex per Share |
0.52 | 0.03 | (0.02) | (0.05) | |
Free Cash Flow per Share |
0.65 | 0.42 | 0.03 | 0.00 | |
Cash per Share |
1.12 | 1.40 | 1.25 | 1.09 | |
Shareholders Equity per Share |
(0.34) | 0.19 | 0.21 | 0.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.34) | 0.19 | 0.21 | 0.32 | |
Free Cash Flow |
5.56 | 3.60 | 0.24 | (0.02) | |
Working Capital |
3.06 | 6.78 | 5.65 | 5.03 | |
Capital Expenditures |
4.48 | 0.28 | (0.16) | (0.45) | |
Net Current Asset Value |
(15.90) | (11.10) | (11.30) | (10.62) | |
EV/EBIT |
75.13 | 53.70 | 49.17 | 63.79 | |
Capex to Sales |
(0.39) | (0.02) | 0.02 | 0.05 | |
Price to Operating Income |
72.04 | 51.68 | 46.13 | 57.27 | |
| Other line items | |||||
Average Receivables |
3.73 | 4.38 | 4.93 | 4.82 | |
Average Payables |
4.06 | 3.49 | 3.74 | 3.66 | |
Average Inventory |
5.12 | 5.04 | 5.68 | 6.49 | |
Average Assets |
28.72 | 33.73 | 33.98 | 34.83 | |
Average Common Equity |
(31.60) | (7.09) | (7.73) | (5.99) |
Columns are period end dates